BONE METASTASES IN BREAST CANCER

s?v cited July 17, 2012] 44. Fallowfield L, Patrick D, Body J, et al. Effects of denosumab versus zoledronic acid (za) on health-related quality of life (hrql) in metastatic breast cancer: results from a random- ized phase iii trial [abstract 1025]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/ Abstracts?v cited July 17, 2012] 45. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double- blind study. Lancet 2011;377:813–22. 46. Verma S, Kerr–Cresswell D, Dranitsaris G, et al. Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian medical oncologists. Support Care Cancer 2004;12:852–8. 47. Fornier MN. Denosumab: second chapter in controlling bone metastases or a new book? J Clin Oncol 2010;28:5127–31. 48. Bouganim N, Dranitsaris G, Amir E, Clemons M. Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer 2011;19:1687–96. 49. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase ii trial evalu- ating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006;24:4895–900. 50. Fizazi K, Lipton A, Mariette X, et al. Randomized phase ii trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564–71. 51. Lipton A, Cook RJ, Major P, Smith MR, Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007;12:1035–43. 52. Saad F, Lipton A. Src kinase inhibition: targeting bone metas- tases and tumor growth in prostate and breast cancer. Cancer Treat Rev 2010;36:177–84. Correspondence to: Alexander H.G. Paterson, 1331–29 Street NW, Calgary, Alberta T2N 4N2 E-mail: Alexander.Paterson@albertahealthservices.ca * Ottawa Regional Cancer Centre, University of Ottawa, Ottawa, ON. † University of British Columbia and BC Cancer Agency, Vancouver, BC. ‡ Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON. § Tom Baker Cancer Centre, University of Calgary, Calgary, AB.